TY - JOUR
T1 - Identification of drug resistance determinants in a clinical isolate of pseudomonas aeruginosa by high-density transposon mutagenesis
AU - Sonnabend, Michael S.
AU - Klein, Kristina
AU - Beier, Sina
AU - Angelov, Angel
AU - Kluj, Robert
AU - Mayer, Christoph
AU - Groß, Caspar
AU - Hofmeister, Kathrin
AU - Beuttner, Antonia
AU - Willmann, Matthias
AU - Peter, Silke
AU - Oberhettinger, Philipp
AU - Schmidt, Annika
AU - Autenrieth, Ingo B.
AU - Schütz, Monika
AU - Bohn, Erwin
N1 - Publisher Copyright:
Copyright © 2020 Sonnabend et al.
PY - 2020
Y1 - 2020
N2 - With the aim to identify potential new targets to restore antimicrobial susceptibility of multidrug-resistant (MDR) Pseudomonas aeruginosa isolates, we generated a high-density transposon (Tn) insertion mutant library in an MDR P. aeruginosa bloodstream isolate (isolate ID40). The depletion of Tn insertion mutants upon exposure to cefepime or meropenem was measured in order to determine the common resistome for these clinically important antipseudomonal β-lactam antibiotics. The approach was validated by clean deletions of genes involved in peptidoglycan synthesis/recycling, such as the genes for the lytic transglycosylase MltG, the murein (Mur) endopeptidase MepM1, the MurNAc/GlcNAc kinase AmgK, and the uncharacterized protein YgfB, all of which were identified in our screen as playing a decisive role in survival after treatment with cefepime or meropenem. We found that the antibiotic resistance of P. aeruginosa can be overcome by targeting usually nonessential genes that turn essential in the presence of therapeutic concentrations of antibiotics. For all validated genes, we demonstrated that their deletion leads to the reduction of ampC expression, resulting in a significant decrease in β-lactamase activity, and consequently, these mutants partly or completely lost resistance against cephalosporins, carbapenems, and acylaminopenicillins. In summary, the determined resistome may comprise promising targets for the development of drugs that may be used to restore sensitivity to existing antibiotics, specifically in MDR strains of P. aeruginosa.
AB - With the aim to identify potential new targets to restore antimicrobial susceptibility of multidrug-resistant (MDR) Pseudomonas aeruginosa isolates, we generated a high-density transposon (Tn) insertion mutant library in an MDR P. aeruginosa bloodstream isolate (isolate ID40). The depletion of Tn insertion mutants upon exposure to cefepime or meropenem was measured in order to determine the common resistome for these clinically important antipseudomonal β-lactam antibiotics. The approach was validated by clean deletions of genes involved in peptidoglycan synthesis/recycling, such as the genes for the lytic transglycosylase MltG, the murein (Mur) endopeptidase MepM1, the MurNAc/GlcNAc kinase AmgK, and the uncharacterized protein YgfB, all of which were identified in our screen as playing a decisive role in survival after treatment with cefepime or meropenem. We found that the antibiotic resistance of P. aeruginosa can be overcome by targeting usually nonessential genes that turn essential in the presence of therapeutic concentrations of antibiotics. For all validated genes, we demonstrated that their deletion leads to the reduction of ampC expression, resulting in a significant decrease in β-lactamase activity, and consequently, these mutants partly or completely lost resistance against cephalosporins, carbapenems, and acylaminopenicillins. In summary, the determined resistome may comprise promising targets for the development of drugs that may be used to restore sensitivity to existing antibiotics, specifically in MDR strains of P. aeruginosa.
KW - AmpC β-lactamase
KW - Antibiotics
KW - Clinical isolate
KW - Multidrug resistance
KW - Peptidoglycan
KW - Peptidoglycan recycling
KW - Pseudomonas aeruginosa
KW - TraDIS
UR - http://www.scopus.com/inward/record.url?scp=85079840153&partnerID=8YFLogxK
U2 - 10.1128/AAC.01771-19
DO - 10.1128/AAC.01771-19
M3 - Article
C2 - 31818817
AN - SCOPUS:85079840153
SN - 0066-4804
VL - 64
JO - Antimicrobial Agents and Chemotherapy
JF - Antimicrobial Agents and Chemotherapy
IS - 3
M1 - e01771-19
ER -